Full year sales at Sigma Aldrich rose 10% to $2.5bn, with the SAFC business growing 9% during the year. The company said it expected the SAFC business to show low to mid single digit growth in the first half of the year and low double digit growth in the second half of the year as additional capacity comes on line in China and Taiwan.
Seeking Alpha
Sunday, 12 February 2012
SAFC continues to grow sales
Revenues rise for AMPAC
AMPAC reported a 55% increase in fine chemicals segment revenues to $21.5m in its Q1 2012. Dana Kelley, AMPAC vice-president, CFO and treasurer, said that revenues from antiviral products were the primary contributor to the rise as the 2012 first quarter included no antiviral product revenue. Joe Carleone, AMPAC president and CEO, said the company had recently agreed to produce controlled substances for a large pharmaceutical customer and will soon be conducting a full scale validation of a chemical product in this area.
Seeking Alpha
Lonza's new factory concept
Lonza is establishing a new manufacturing concept at its Vis, Switzerland site. The company said that continuous flow and microreactor technologies will allow it to offer increased flexibility and capacity for the development and manufacture of APIs. Lonza added that the facility will be ready for full operation in June 2012.
Manufacturing Chemist
Contract manufacturing sales up for AMRI
Contract manufacturing sales at AMRI rose in 2011. The company reported a rise of 4% to $36m for its development and small scale manufacturing and 20% to $95.6m for large scale manufacturing.
AMRI
Sales rise at Cambrex; looks to acquire
Cambrex reported a sales rise of almost 6% to $67.1m in Q4 2011, which the company attributed to increased demand for an API manufactured under a long-term supply agreement, a recently approved innovator product, higher sales of generic APIs, and higher volumes of controlled substances and products utilising its drug delivery technology. Cambrex CEO, Steven Klosk, said the company is looking to add further capabilities in generic finished products.
In-pharma Technologist
Saturday, 11 February 2012
Codexis looks to future
Codexis' full year 2011 product revenue rose 49% to $49.0m as a result of increased sales to both generic and innovator pharmaceutical customers. Codexis President and CEO, Alan Shaw, said that in 2012 the Codexis' customers received FDA and EMA approvals for three new on-patent drugs using the company's technology. Shaw said he expects to see improved sales growth in 2012. Additionally he said Codexis is expecting the FDA to approve the manufacturing process for blockbuster pharmaceutical product, which has approaching $4bn in sales. He sees additional growth from increased volumes of generic atorvostatin using the company's technology and more companies using their products in their process development.
Codexis
Wednesday, 8 February 2012
New contract for Angel
Angel biotechnology has signed three new manufacturing contracts with Materia Medica Holding, worth £4.5m. Angel will start the projects at its Edinburgh facility before transferring later this year to its refurbished, larger site at Cramlington, UK.
The Herald
Aesica to expand HPAPI capabilities
Aesica is to upgrade its API manufacturing capabilities to enable the company to manufacture high potency APIs at commercial scale. Following the upgrade, Aesica will be able to manufacture SafeBridge Category 3 API and formulated products from pilot to commercial scale at two of its sites in Europe.
Aesica
Thursday, 2 February 2012
Wednesday, 1 February 2012
Q3 sales rise at Johnson Matthey
Johnson Matthey's fine chemicals division reported sales up 15% to £62m in its Q3 ended 31 December 2011. The company said its API manufacturing business performed well aided by sales of a new API for the treatment of drug addiction. Looking forward Matthey said the underlying performance of the division is more predictable and it continues in line with expectations.
Johnson Matthey
SAFC gets BioReliance
Sigma-Aldrich has completed its acquisition of BioReliance from Avista Capital Partners for $350m. BioReliance's services will be folded into Sigma-Aldrich's SAFC custom manufacturing and services business unit.
Maryland Daily Record
Tuesday, 31 January 2012
Indian manufacturing pact for DSM
Mumbai, India-based Indoco Remedies will manufacture eight APIs for DSM's pharmaceutical products business unit. DSM said the alliance will leverage Indoco's product development and cGMP manufacturing capabilities and DSM's market access. Additionally DSM said the deal fits with its global expansion plans.
Hindu Business Line
Wednesday, 25 January 2012
Lonza results miss estimates, fires CEO
Lonza has reported its full year 2011 revenues before the Arch acquisition of CHF2.5m, up 5% in constant exchange rates, missing analyst estimates. The company also announced that its CEO, Stefan Borgas, would be leaving the company with immediate effect. Lonza's share price fell 13% on the day the results were announced.
Lonza said its custom manufacturing continued to benefit from demand for outsourcing from pharmaceutical and biotech companies. The company said its capacity utilisation rate for small molecules was 78% and for biological molecules was 87% excluding the recently opened Singapore facility and it had increased the number of contracts it had signed.
Outsourcing Pharma
Strong year for Albemarle
Albemare reported a strong Q4 and full year 2011 for its fine chemistry business unit. Sales in Q4 rose 36% to $209m and income 62% to $43m. For the full year the unit reported record sales of$750m up 32% and income doubles to $140m. The company said that the unit is set for another strong year in 2012.
Seeking Alpha
Monday, 23 January 2012
Thursday, 19 January 2012
Avecia Biotechnology plans acquisition
Avecia Biotechnology has identified a possible acquisition target that would expand its capabilities. Company President Detlef Rethage said it has chosen a company in the fill and finish business. Avecia has not indicated when the acquisition would be completed.
Mass High Tech
AMRI UK site receives GMP certificate
AMRI’s Holywell, UK, manufacturing facility has received a GMP certificate following an inspection in October 2011. The site also passes a US FDA audit in June 2011. AMRI said the former Excelsyn facility can now produce registered intermediates and active ingredients for use in humans and expands the range of projects that it can now conduct at this facility.
AMRI
Tuesday, 17 January 2012
Molecular Profiles to expand cGMP capacity
Molecular Profiles is adding a new £9m manufacturing facility at its Nottingham, UK, site. The new facility, which is due to open later this year, will add 3000m2 of space and provide six new GMP suites, new laboratories and a clinical packing suite. It is designed to enable flexibility of use and the manufacture of highly potent compounds up to OEB 4 level.
InPharm
Carbogen Amcis acquires Creapharm
Dishman Pharmaceuticals subsidiary Carbogen Amcis has acquired Creapharm Parenterals for an undisclosed sum. The business, which will be renamed Carbogen Amcis SAS, adds complimentary formulation and lyophilisation services as well as sterile GMP-standard capabilities for the rapid supply of medicines, including highly potent compounds for preclinical and clinical trials to Carbogen Amcis.
Pharma Times
Monday, 16 January 2012
Tuesday, 10 January 2012
Future of AMRI's Hungary facility in doubt
AMRI is considering options for its custom research and manufacturing facility in Budapest, Hungary. The company said the site had been losing money over the last two years and the company is considering transferring the activities to other sites.
Outsourcing Pharma
Monday, 9 January 2012
Thursday, 5 January 2012
Wednesday, 4 January 2012
Wednesday, 28 December 2011
AMRI restructures for 2012
AMRI is to take additional actions to streamline its operations in 2012. During Q4 2011 AMRI has reduced its workforce, reduced capacity and reduced operating costs. The company hopes these actions "will better align the business to current and expected market conditions and are expected to improve the company’s overall cost competitiveness and increase cash flow generation". AMRI said the reduction will primarily affect its US operations and will terminate the lease of one of its US facilities. AMRI expects that these cost-reduction initiatives will result save $10-11m per year.
Times Union
Tuesday, 20 December 2011
Sunday, 18 December 2011
GE and M+W to build biopharma manufacturing plants
GE Healthcare and M+W Group have formed a partnership to offer an integrated, "turn-key" approach for the construction of biopharmaceutical manufacturing plants, to help meet the rapidly increasing worldwide demand for these potentially life-saving treatments. The alliance is targeted at emerging countries.
Bloomberg BusinessWeek
Lonza expands early phase manufacturing in China
Lonza has completed the expansion of it snarly phase manufacturing capacity in Nansha, China. Lonza has added a new cGMP kilo-lab and an additional small scale train to meet the growing demands of its global small molecule customers.
Manufacturing Chemist
Tuesday, 13 December 2011
EMA and FDA to collaborate on GMP inspections
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) are to share work on inspections of manufacturing sites in each other's territories, starting in January 2012. The initiative builds on a pilot programme which ran earlier this year. Initially the programme will focus on inspections of manufacturing sites in the EU or US that are already known to the two authorities and have a history of compliance with GMP following previous inspections.
InPharm
Australian biologics facility moves closer
DSM Biologics and the University of Queensland’s Australian Institute for Bioengineering and Nanotechnology (AIBN) have signed a memorandum of understanding to construct and run Australia’s largest biologics scale-up facility in Brisbane. The Aus$65m facility, which is currently under construction, will be owned by Biopharmaceuticals Australia and will be run by DSM Biologics. The AIBN will collaborate on early stage biologics development.
Australian Life Scientist
Wednesday, 7 December 2011
Novasep restructures balance sheet
Novasep has completed a restructuring of its balance sheet with its creditors. Additionally the French Fonds Stratégigue d’Investissement (French Strategic Investment Fund) has become a new investor in the company, which as abandoned its plans to merge with Minakem.
Speciality Chemicals
Tuesday, 6 December 2011
Shasun aims for growth
Shasun Pharmaceuticals Managing Director S Abhaya Kumar has said the company aims to double its annual revenues to $389m, within four years, by increasing exports. The company is currently adding new API manufacturing capacity in Vizag, India, and expanding capacity in Newcastle, UK.
Economic Times
Monday, 5 December 2011
Thursday, 1 December 2011
Vivimed acquires Uquifa
Vivimed Labs has acquired Yule Catto's Uquifa pharmaceutical ingredients business for £35m. Uquifa operates three manufacturing sites, two in Spain and one in Mexico. Mark Robbins will remain CEO of Uquifa. Vivimed said the acquisition would strengthen its current position in pharma APIs and intermediates while significantly improving the cost competitiveness of Uquifa.
Economic Times
Wednesday, 30 November 2011
Sales fall at Dottikon
Dottikon reported H1 sales fell by 14% year-on-year to CHF30.8m and a net loss of CHF2.7m. The company said it had reached its "prospective bottom" and had ended short hours working.
Dottikon
Thursday, 24 November 2011
Strong sales for Johnson Matthey
Johnson Matthey's Fine Chemicals division reported sales 16% higher at £142m in the six months ended 30 September. The company said its return on sales fell slightly as a result of the impact of a restructuring programme at Macfarlan Smith. Johnson Matthey is planning to use its Conshohocken, US, facility to manufacture intermediates and final products at lower cost and higher efficiency, enabling the company to rationalise global production and secure new business which could not have been targeted previously.
Johnson Matthey
Tuesday, 22 November 2011
Aesica opens potent products plant
Aesica has opened its £3m manufacturing facility for potent products in Queenborough, Kent, UK. Aesica said the new facility will significantly enhance and extend its capabilities in terms of formulated products and the packaging of solid dosage forms. The new facility gives Aesica the capability to manufacture products classified as SafeBridge Category 3 and Schedule II controlled drugs such as opiates.
Kent Online
Tuesday, 15 November 2011
Thursday, 10 November 2011
UK companies receive government support
Aesica Pharmaceuticals, Piramal Healthcare and Shasun Pharma are to share £2m of funding from the UK government's Regional Growth Fund with two other companies. The companies will use the funding to expand their international activities.
News Post Leader
Tuesday, 8 November 2011
Manufacturing revenues up for AMRI
AMRI reported a flat Q3 2011 with sales of $50.2m, however sales for its manufacturing services rose. AMRI's development/small-scale manufacturing revenue was up 8% to $9.2m and large-scale manufacturing revenue increased 17% to $25.7m.
AMRI
Cobra acquires Unitech
Cobra Biologics has acquired Unitech Pharma Group and its bio-production facility in Matfors, Sweden. The company said the acquisition is part of its strategy to expand its service offering. The Matfors facility will which add a 600L clinical and commercial microbial GMP production capacity, commercial aseptic fill/finish and lyophilisation capability to Cobra's portfolio.
Outsourcing Pharma
Strong Q3 sales at Cambrex
Cambrex reported that sales in Q3 2011 rose 18% to $58.2m including a 7% rise due to favourable exchange rates. The company said that higher volumes of an API for a customer who experienced a disruption in its supply chain for most of 2010, higher volumes of controlled substances, products utilising its drug delivery technology and a recently approved innovator product were the main reasons for the rise. These were partially offset by lower pricing across several product categories, lower sales of generic APIs and lower custom development shipments.
Cambrex
Thursday, 3 November 2011
Wednesday, 2 November 2011
Tuesday, 1 November 2011
Chemie Uetikon acquired by Barclays and management
Barclays Private Equity has acquired a majority shareholding in CU Chemie Uetikon from CPH Chemie + Papier Holding AG. Barclays, which has acquired 90% of the Lahr, Germany-based company, said it and the company's management will pursue a consistent growth strategy in pharmaceuticals, cosmetics and nutrition industries.
Uetikon
Capacity utilisation up at Lonza
In its Q3 2011 business update Lonza said its underlying business appears on track to deliver growth through 2011. The company said that capacity utilisation in its pharma-facing custom manufacturing businesses remains high - about 90% for biologics and about 83% for chemicals. The company said it still faces challenges from the strength of the Swiss Franc, raw material headwinds and continued competition in life science intermediates.
Reuters
Monday, 31 October 2011
Fujifilm to manufacture ContraFect biologic
Fujifilm Diosynth Biotechnologies will use its pAVEway advanced protein expression technology at its Billingham, UK, facility to support the process development and cGMP manufacture of CF-301, ContraFect’s Staphylococcal-specific bacteriophage lysine.
Manufacturing Chemist
Lonza to manufacture GenMab's HuMax-TF
Lonza will provide process development and cGMP manufacturing for Genmab’s monoclonal antibody HuMax-TF in its Slough, UK facility. The antibody, which is expressed using Lonza’s GS Gene Expression System, will be conjugated at Lonza's plant in Visp, CH to a cytotoxic drug to form the antibody drug conjugate.
GEN
Monday, 24 October 2011
Almac to increase manufacturing capacity
Almac is expanding manufacturing capacity to over 30m3 at its Craigavon, UK, headquarters. The company said the facility will include reactor vessels with state of the art clean room product isolation and drying equipment to allow HPAPI manufacture up to 600kg batch size. Almac anticipates that the facility will be built, commissioned and validated within the next two years.
Almac
Layoffs at Corden
Corden Pharma Colorado, the former Roche Colorado facility recently acquired by ICIG, is to lay off 60 of its 260 workers.
Boulder County Business Report
Thursday, 20 October 2011
Almac to expand pharmaceutical development capabilities
Almac will invest £4.5m in the first phase of expanding pharmaceutical development capabilities at its headquarters in Craiavon, Northern Ireland. The new laboratory scale facility, which is due for completion in mid-2012, will provide non-GMP formulation facility for the development and scale-up of solid oral dose drug products using a range of technologies. The second stage of the expansion will add dedicated analytical laboratories before the end of 2012.
Genetic Engineering and Biotechnology News
Carbogen Amcis and Polymun Scientific to team on HPAPI technologies
Carbogen Amcis will collaborate with Polymun Scientific to offer additional services for the development, manufacturing and formulation of HPAPIs. Carbogen Amcis will gain access to Polymun's innovative liposome technology for the formulation of APIs and Polymun will have access to Carbogen Amcis' expertise in the development and manufacture of highly potent APIs.
Carbogen Amcis
Wednesday, 19 October 2011
Hovione collaborates with Bend Research
Hovione and Bend Research will collaborate to offer their clients access to each other's capabilities. Bend Research will offer its clients access to Hovione’s commercial-scale pharmaceutical manufacturing facilities and Hovione clients will have access to Bend Research’s oral drug-delivery, formulation, and engineering expertise.
Bend Research
Monday, 17 October 2011
Angel to establish jv
Angel Biotechnology is to establish a joint venture with Materia Medica Holding (MMH). The jv, which will be 51% owned by MMH and 49% owned by Angel, will commission new product programmes and manage their production in a dedicated GMP unit operated by Angel, on behalf of MMH. To manufacture products for MMH, Angel plans to increase the size of the GMP facility at Cramlington.
Proactive Investors
Profits fall at Aesica
Aesica's pre-tax profit in 2010 fell from £9.7m to £3.4m as sales fell slightly from £84.6m to £83.5m. The company said the closure of its Ponders End facility in London generated exceptional costs of £6.8m, including £3.1m primarily relating to redundancy payments.
Insider Media, Yorkshire
Saltigo to add HPAPI manufacturing capabilities
Saltigo is adding the capabilities to produce potent and highly potent APIs at its Redmond, WA, facility. Andreas Stolle, head of Saltigo's pharma business line, said the kilogram scale facility, aimed at supplying materials for phase I and II, will be available early in 2012. Additionally, Saltigo's Leverkusen site has been accredited by the Japanese Pharmaceuticals and Medical Devices Agency.
Saltigo
Wednesday, 5 October 2011
Carbogen Amcis completes inspection
Carbogen Amcis has successfully completed a US FDA pre-approval inspection for a new high potency drug. for a US multinational. Dishman's managing director JR Vyas said: "Post this approval, we expect business of around $10m per annum from our existing customers."
Money Control
Aesica gets new investor plans expansion
Silverfleet Capital has replaced LDC as the majority investor in Aesica. Silverfleet's investment will enable Aesica to continue its rapid expansion into new markets and achieve its vision of becoming the number one supplier of APIs and formulated products to the global pharmaceutical industry.
Contract Pharma
Subscribe to:
Posts (Atom)
